CHO PHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.2 TWD | -0.36% |
|
-4.00% | -20.35% |
| Mar. 20 | CHO Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | CHO Pharma, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 60K 1.84K | Sales 2023 | - | Capitalization | 14.83B 455M |
|---|---|---|---|---|---|
| Net income 2022 | -338M -10.38M | Net income 2023 | -306M -9.39M | EV / Sales 2022 | 402,853 x |
| Net cash position 2022 | 1.03B 31.71M | Net cash position 2023 | 2.6B 79.89M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-74.5
x | P/E ratio 2023 |
-43.3
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.36% | ||
| 1 week | -4.00% | ||
| Current month | -7.38% | ||
| 1 month | -11.40% | ||
| 3 months | -15.08% | ||
| 6 months | -28.87% | ||
| Current year | -20.35% |
1 week
54.60
58.70
1 month
53.3061.50
Current year
51.7070.20
1 year
51.70106.50
3 years
25.95251.50
5 years
12.90251.50
10 years
12.90251.50
| Managers | Title | Age | Since |
|---|---|---|---|
Tsung I Wu
CEO | Chief Executive Officer | - | - |
Chao-Long Chen
CHM | Chairman | - | 17-12-26 |
Yi Pei Chou
DFI | Director of Finance/CFO | - | 16-03-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ming Hsing Tsai
BRD | Director/Board Member | 66 | 13-05-26 |
Hsuan Ta Liu
BRD | Director/Board Member | - | 19-06-05 |
Chao-Long Chen
CHM | Chairman | - | 17-12-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.36% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 55.2 | -0.36% | 155 192 |
| 24-04-25 | 55.4 | -1.95% | 239,770 |
| 24-04-24 | 56.5 | +1.99% | 387,702 |
| 24-04-23 | 55.4 | -0.18% | 255,419 |
| 24-04-22 | 55.5 | +1.46% | 582,888 |
End-of-day quote Taipei Exchange, April 25, 2024
More quotes
CHO PHARMA INC. is principally engaged in the development of new drugs related to sugar molecules. The companyâs technology and development can be divided into eight categories according to its patent features, including homogeneous antibody drugs, monoclonal antibodies of cancers and immune-related diseases, carbohydrate-related vaccines and drugs, anti-influenza drugs, the development and application of Saccharin tablets, the development and application of sugar probes, the synthesis identification development and application of sugar molecular, as well as the derivative patents of innovation development plans.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -20.35% | 364M | |
| -4.66% | 87.53B | |
| +1.32% | 40.42B | |
| -19.07% | 29.48B | |
| +57.86% | 25.43B | |
| -17.58% | 11.49B | |
| -43.00% | 11.3B | |
| -9.14% | 11.1B | |
| +5.24% | 8.75B | |
| -8.42% | 7.99B |
- Stock Market
- Equities
- 6586 Stock
